Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | CFO and Treasurer | February 25, 2025 | February 27, 2025 |
| Faeth Therapeutics, Inc.FTH · Entity 5029 | Chief Financial Officer | June 29, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date February 25, 2025 · Filed February 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,464 |
Ending reported balance
After 2025-02-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-02-25 · Exercise / conversion · Acquired 8,500 · Balance 110,964 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. Row 2 · 2025-02-25 · Sale · Disposed 8,400 · Balance 102,564 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F2: Represents the weighted average sale price of the shares sold from $32.63 to $33.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Row 3 · 2025-02-25 · Sale · Disposed 100 · Balance 102,464 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2029-06-26 | Direct | 440,170 |
Reported balance
After 2025-02-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-25 · Exercise / conversion · Disposed 8,500 · Balance 440,170 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F3: The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
F2: Represents the weighted average sale price of the shares sold from $32.63 to $33.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023.
Faeth Therapeutics, Inc.
Report date June 29, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 46,688 |
Last balance in matching sequence
After 2026-07-01 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2026-06-29 · Purchase · Acquired 831 · Balance 33,885 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.20 to $23.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 2 · 2026-06-30 · Purchase · Acquired 1,910 · Balance 35,795 F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.45 to $23.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 3 · 2026-06-30 · Purchase · Acquired 1,638 · Balance 37,433 F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $24.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 4 · 2026-06-30 · Purchase · Acquired 4,255 · Balance 41,688 F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 5 · 2026-07-01 · Purchase · Acquired 4,400 · Balance 46,088 F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.14 to $23.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 6 · 2026-07-01 · Purchase · Acquired 600 · Balance 46,688 F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.14 to $24.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.20 to $23.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.45 to $23.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $24.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.14 to $23.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.14 to $24.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2020 Filed Nov 19, 2020 00:43 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 592 | $44.33 | $26,243.36 |
DisclosureSEC source: 0000899243-20-031555 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,085 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 1,710 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:43 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 1,710 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031555 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 22:59 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,709 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022786 · doc4.xml · derivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,647 Underlying: Common Stock · 1,709 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. F4 · derivative.expiration_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 22:59 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 591 | $28.53 | $16,861.23 |
DisclosureSEC source: 0000899243-20-022786 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,967 F3 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,709 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 22:59 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 1,709 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-022786 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 733 shares acquired by the Reporting Person on August 14, 2020 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 22:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 403 | $27.54 | $11,098.82 |
DisclosureSEC source: 0000899243-20-021557 · doc4.xml · nonDerivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,116 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F5 · price: Represents the weighted average sale price of the shares sold from $27.51 to $27.69 per share. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 22:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,136 | $27.20 | $58,097.49 |
DisclosureSEC source: 0000899243-20-021557 · doc4.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,519 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $26.46 to $27.45 per share. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 22:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 200 | $28.30 | $5,659.00 |
DisclosureSEC source: 0000899243-20-021557 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,655 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F3 · price: Represents the weighted average sale price of the shares sold from $28.09 to $28.50 per share. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 22:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 4,461 | $27.22 | $121,433.33 |
DisclosureSEC source: 0000899243-20-021557 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,855 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $26.78 to $27.63 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 5. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:29 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 100 | $32.49 | $3,249.00 |
DisclosureSEC source: 0000899243-20-018485 · doc4.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,316 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:29 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,800 | $31.68 | $88,712.12 |
DisclosureSEC source: 0000899243-20-018485 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,416 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F3 · price: Represents the weighted average sale price of the shares sold from $31.28 to $32.11 per share. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:29 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 7,900 | $30.64 | $242,091.55 |
DisclosureSEC source: 0000899243-20-018485 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,216 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $30.17 to $31.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,000 | $30.00 | $60,001.60 |
DisclosureSEC source: 0000899243-20-015951 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,116 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $30.00 to $30.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 23:59 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 27,356 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015540 · doc4.xml · derivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,356 Underlying: Common Stock · 27,356 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. In general, 6.25% of the RSUs will vest on August 16, 2020 and 6.25% will vest in quarterly installments on the 16th day of February, May, August and November, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through the applicable vesting date. F5 · derivative.expiration_date: The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. In general, 6.25% of the RSUs will vest on August 16, 2020 and 6.25% will vest in quarterly installments on the 16th day of February, May, August and November, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through the applicable vesting date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 23:59 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 196,850 | $0.00 Strike: $28.86 | $0.00 |
DisclosureSEC source: 0000899243-20-015540 · doc4.xml · derivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,850 Underlying: Common Stock · 196,850 shares Expires 2030-06-02 F3 · derivative.exercise_date: The Option will vest over approximately four years. 1/48th of the shares of Common Stock underlying the Option will vest on a monthly basis after June 3, 2020 (the "Vesting Commencement Date"), such that all of the shares underlying the Option will be vested on the date four (4) years after the Vesting Commencement Date, subject to the Reporting Person's continued Service Relationship (as defined in the Plan) with the Issuer or any of its subsidiaries through the applicable vesting date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 23:59 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,600 | $30.04 | $48,071.84 |
DisclosureSEC source: 0000899243-20-015540 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,116 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $30.00 to $30.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 900 | $29.74 | $26,768.07 |
DisclosureSEC source: 0000899243-20-015043 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,716 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F3 · price: Represents the weighted average sale price of the shares sold from $29.66 to $29.875 per share. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 6,300 | $29.31 | $184,632.84 |
DisclosureSEC source: 0000899243-20-015043 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,616 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $28.66 to $29.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document |
| May 05, 2020 Filed May 7, 2020 00:26 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,706 | $30.49 | $173,959.39 |
DisclosureSEC source: 0000899243-20-012195 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,916 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $30.09 to $31.05 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2020 Filed May 5, 2020 10:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,494 | $30.00 | $44,827.17 |
DisclosureSEC source: 0000899243-20-011989 · doc4.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,622 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $30.00 to $30.02 per share. Read SEC document |
| May 01, 2020 Filed May 5, 2020 10:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,200 | $29.83 | $35,794.56 |
DisclosureSEC source: 0000899243-20-011989 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,116 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F3 · price: Represents the weighted average sale price of the shares sold from $29.71 to $30.14 per share. Read SEC document |
| May 01, 2020 Filed May 5, 2020 10:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 6,000 | $29.11 | $174,679.80 |
DisclosureSEC source: 0000899243-20-011989 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,316 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $28.71 to $29.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:11 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,286 | $27.74 | $35,677.11 |
DisclosureSEC source: 0000899243-20-010120 · doc4.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,316 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $27.50 to $28.18 per share. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:11 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,500 | $26.86 | $67,149.00 |
DisclosureSEC source: 0000899243-20-010120 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,602 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F3 · price: Represents the weighted average sale price of the shares sold from $26.44 to $27.42 per share. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:11 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 3,414 | $26.01 | $88,783.46 |
DisclosureSEC source: 0000899243-20-010120 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,102 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $25.43 to $26.41 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:11 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 290 | $33.31 | $9,659.99 |
DisclosureSEC source: 0000899243-20-006945 · doc4.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,516 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $33.27 to $33.36 per share. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:11 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,550 | $32.65 | $181,179.75 |
DisclosureSEC source: 0000899243-20-006945 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,806 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F3 · price: Represents the weighted average sale price of the shares sold from $32.27 to $33.25 per share. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:11 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 4,960 | $31.79 | $157,701.22 |
DisclosureSEC source: 0000899243-20-006945 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,356 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $31.26 to $32.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4. Read SEC document |
| February 04, 2020 Filed Feb 5, 2020 21:57 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 4,973 | $34.52 | $171,692.33 |
DisclosureSEC source: 0000899243-20-003289 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,316 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F3 · price: Represents the weighted average sale price of the shares sold from $34.18 to $35.08 per share. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:57 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,827 | $34.90 | $203,378.62 |
DisclosureSEC source: 0000899243-20-003289 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,289 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $34.47 to $35.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 01:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 3,536 | $32.31 | $114,246.04 |
DisclosureSEC source: 0000899243-20-000654 · doc4.xml · nonDerivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,116 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on [December 3, 2019]. F6 · price: Represents the weighted average sale price of the shares sold from $32.00 to $32.99 per share. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 01:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 100 | $31.94 | $3,194.00 |
DisclosureSEC source: 0000899243-20-000654 · doc4.xml · nonDerivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,652 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on [December 3, 2019]. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 01:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 30 | $35.17 | $1,055.10 |
DisclosureSEC source: 0000899243-20-000654 · doc4.xml · nonDerivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,752 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on [December 3, 2019]. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 01:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 622 | $34.23 | $21,292.68 |
DisclosureSEC source: 0000899243-20-000654 · doc4.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,782 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on [December 3, 2019]. F5 · price: Represents the weighted average sale price of the shares sold from $34.08 to $34.40 per share. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 01:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 4,217 | $33.47 | $141,156.06 |
DisclosureSEC source: 0000899243-20-000654 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,404 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on [December 3, 2019]. F4 · price: Represents the weighted average sale price of the shares sold from $33.07 to $34.065 per share. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 01:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,295 | $32.57 | $74,739.43 |
DisclosureSEC source: 0000899243-20-000654 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,621 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on [December 3, 2019]. F2 · price: Represents the weighted average sale price of the shares sold from $32.02 to $33.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5 and 6. F3 · balance_after: Includes 1,470 shares acquired by the Reporting Person on December 31, 2019 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionManagement Incentive Units · Derivative | 18,240 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019140 · doc4.xml · derivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · See Remark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,240 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionManagement Incentive Units · Derivative | 294,706 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019140 · doc4.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · See Remark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 294,706 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F2 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of October 29, 2018, such that the shares shall be fully vested on October 29, 2023, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | PurchaseCommon Stock | 55,500 | $17.00 | $943,500.00 |
DisclosureSEC source: 0000899243-19-019140 · doc4.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,446 Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 18,240 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019140 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 294,706 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019140 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of October 29, 2018, such that the shares shall be fully vested on October 29, 2023, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.